Carestream Dental vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Digital dental imaging and practice management software provider offering intraoral sensors, 3D imaging systems, and clinical software for dental practices and institutions worldwide.
About
Carestream Dental is a Rochester, New York-based provider of dental imaging technology and practice management software, operating as a business unit spun off from Carestream Health. The company offers a comprehensive portfolio of dental imaging solutions spanning intraoral X-ray sensors, panoramic imaging systems, 3D cone beam CT (CBCT) scanners, and the clinical software required to acquire, store, manage, and interpret dental images. Carestream Dental serves general dental practices, specialty clinics, dental schools, and group dental organizations globally.\n\nThe company's imaging software platforms, including CS Imaging and CS PracticeWorks, integrate clinical image management with practice workflow features such as patient scheduling, charting, and treatment planning. This integration between imaging hardware and software creates a vertically integrated ecosystem that encourages multi-product adoption within a single practice. Carestream Dental has built a significant installed base in North America and Europe over several decades of operation as part of larger parent organizations including Kodak and Carestream Health.\n\nCarestream Dental competes in the dental technology market against companies such as Dentsply Sirona, Planmeca, and Patterson Companies. The transition from film-based to digital radiography was a key growth driver historically, and the company now focuses on 3D imaging adoption, digital impression workflow integration, and cloud-connected imaging tools. Its deep roots in imaging hardware combined with proprietary software give it a bundled solution advantage when selling into practices upgrading their full radiography infrastructure.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.